Herbert Moessler, Ph.D.
Chairman of the Board of Directors
Dr. Herbert Moessler is one of the founding members of Neuropore Therapies, Inc. and currently serves as the Chairman of the Board of Directors. He is also an advisor for the EVER Pharma Group in Austria. Dr. Moessler has extensive experience with all aspects of international pharma business and has devoted his professional career to the development, marketing and sales of therapeutic agents and health products for neurological disorders. Prior to his current assignments, he held the positions of CEO of Neuropore Therapies, CEO of EVER Neuro Pharma, Austria and Staff Scientist at the Institute of Molecular Biology of the Austrian Academy of Sciences.
He received his PhD in Molecular Biology and Genetics from the University of Salzburg, Austria, and his MBA from the Danube University in Krems, Austria.
Joseph S. McCracken, DVM, MS
Joe McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives; and serves on the Boards of Alkahest, Inc., Modalis Therapeutics, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011, he was General Manager, Roche Pharma Japan & Asia Regional Head, and Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for nearly 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer.
Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.